Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization.
Using growth factors to induce vasculogenesis is a promising approach in the treatment of ischemic legs and myocardium. Because the vasculogenesis requires a cascade of growth factors, their receptors, and intracellular signals, such therapies may require the application of more than a single growth factor. We examined the effect of 2 endothelial cell-specific growth factors, angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF), on primary cultured porcine coronary artery endothelial cells. VEGF, but not Ang1, increased DNA synthesis and cell number. Ang1 or VEGF induced migration and sprouting activity, increased plasmin and matrix metalloproteinase-2 secretion, and decreased tissue inhibitors of metalloproteinase type 2 secretion. A combination of the submaximal doses of Ang1 and VEGF enhanced these effects and was more potent than the maximal dose of either alone. In a rabbit ischemic hindlimb model, a combination of Ang1 and VEGF gene delivery produced an enhanced effect on resting and maximal blood flow and capillary formation that was greater than that of either factor alone. Angiographic analyses revealed that larger blood vessels were formed after gene delivery of Ang1 or Ang1 plus VEGF than after VEGF gene delivery. These results suggest that combined treatment of Ang1 and VEGF could be used to produce therapeutic vascularization.
Chae
J K
JK
National Creative Research Initiatives Center for Cardiac Regeneration and Institute of Cardiovascular Research, Chonbuk University Medical School, Chonju, Korea.
Kim
I
I
Lim
S T
ST
Chung
M J
MJ
Kim
W H
WH
Kim
H G
HG
Ko
J K
JK
Koh
G Y
GY
D042683:Angiopoietin-1; D000818:Animals; D002452:Cell Count; D002460:Cell Line; D002465:Cell Movement; D003331:Coronary Vessels; D004247:DNA / Q000096:biosynthesis; D004195:Disease Models, Animal; D004357:Drug Synergism; D016228:Endothelial Growth Factors / Q000235:genetics / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D005341:Fibrinolysin / Q000378:metabolism; D018014:Gene Transfer Techniques; D006614:Hindlimb; D008222:Lymphokines / Q000235:genetics / Q000494:pharmacology*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000235:genetics / Q000494:pharmacology*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010957:Plasmids; D011817:Rabbits; D013552:Swine; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D042683:Angiopoietin-1; D016228:Endothelial Growth Factors; D008222:Lymphokines; D008562:Membrane Glycoproteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D004247:DNA; D005341:Fibrinolysin; D020778:Matrix Metalloproteinase 2